Programme |
EVT201 |
Therapeutic area/Indication |
CNS - Insomnia (GABA-A) |
Partner |
JingXin |
Status |
Phase III |
Programme |
Eliapixant (BAY1817080) |
Therapeutic area/Indication |
Chronic cough (P2X3) |
Partner |
Bayer |
Status |
Phase II |
Programme |
Eliapixant (BAY1817080) |
Therapeutic area/Indication |
Overactive bladder (P2X3) |
Partner |
Bayer |
Status |
Phase II |
Programme |
Eliapixant (BAY1817080) |
Therapeutic area/Indication |
Diabetic neuropathic pain (P2X3) |
Partner |
Bayer |
Status |
Phase II |
Programme |
Eliapixant (BAY1817080) |
Therapeutic area/Indication |
Endometriosis (P2X3) |
Partner |
Bayer |
Status |
Phase II |
Programme |
CT7001 |
Therapeutic area/Indication |
Oncology (CDK7) |
Partner |
Carrick |
Status |
Phase II |
Programme |
EVT401 |
Therapeutic area/Indication |
Immunology & Inflammation (P2X7) |
Partner |
CONBA Group |
Status |
Phase I |
Programme |
BAYxxx |
Therapeutic area/Indication |
Gynaecology |
Partner |
Bayer |
Status |
Phase I |
Programme |
BAYxxx |
Therapeutic area/Indication |
Multiple indications |
Partner |
Bayer |
Status |
Phase I |
Programme |
BAY2328065 |
Therapeutic area/Indication |
Gynaecology |
Partner |
Bayer |
Status |
Phase I |
Programme |
BI 894416 |
Therapeutic area/Indication |
Respiratory (ND) |
Partner |
Boehringer Ingelheim |
Status |
Phase I |
Programme |
BI 860585 |
Therapeutic area/Indication |
Oncology (mTORC1/2) |
Partner |
Boehringer Ingelheim/Xynomic Pharmaceuticals |
Status |
Phase I |
Programme |
TPM203 |
Therapeutic area/Indication |
Pemphigus Vulgaris (ND) |
Partner |
Topas Therapeutics |
Status |
Phase I |
Programme |
DSP-1181 |
Therapeutic area/Indication |
OCD (5-HT1A) |
Partner |
Exscientia |
Status |
Phase I |
Programme |
CNTX 6016 |
Therapeutic area/Indication |
Pain (CB2) |
Partner |
Boehringer Ingelheim/Centrexion |
Status |
Phase I |
Programme |
EVT894 |
Therapeutic area/Indication |
Chikungunya (ND) |
Partner |
Sanofi/NIH |
Status |
Phase I |
Programme |
BAYxxx |
Therapeutic area/Indication |
Women`s health - Endometriosis (ND) |
Partner |
Bayer |
Status |
Pre-clinical |
Programme |
EVT801 |
Therapeutic area/Indication |
Oncology (VEGFR3) |
Partner |
Sanofi |
Status |
Pre-clinical |
Programme |
APN411 |
Therapeutic area/Indication |
Oncology - Immunotherapy (ND) |
Partner |
Sanofi/Apeiron |
Status |
Pre-clinical |
Programme |
QRB001 |
Therapeutic area/Indication |
Diabetes - beta cell replacement therapy |
Partner |
Currently unpartnered |
Status |
Pre-clinical |
Programme |
EXS21546 |
Therapeutic area/Indication |
Oncology (ND) |
Partner |
Exscientia |
Status |
Pre-clinical + several discovery programmes |
Programme |
GLPGxxx |
Therapeutic area/Indication |
Fibrosis (ND) |
Partner |
Galapagos |
Status |
Pre-clinical |
Programme |
BMSxxx |
Therapeutic area/Indication |
Neurodegeneration (ND) |
Partner |
Bristol Myers Squibb |
Status |
Pre-clinical |
Programme |
BAYxxx |
Therapeutic area/Indication |
Nephrology (ND) |
Partner |
Bayer |
Status |
Pre-clinical |
Programme |
TPM501 |
Therapeutic area/Indication |
Celiac disease |
Partner |
Topas Therapeutics |
Status |
Pre-clinical |
Programme |
Various |
Therapeutic area/Indication |
CNS, Metabolic, Pain ...... |
Partner |
>10 further programmes |
Status |
Pre-clinical |
Programme |
Various |
Therapeutic area/Indication |
Nephrology |
Partner |
Bayer |
Status |
Discovery |
Programme |
Various |
Therapeutic area/Indication |
Immunology & Inflammation |
Partner |
UCB |
Status |
Discovery |
Programme |
Various |
Therapeutic area/Indication |
Neurodegeneration |
Partner |
Bristol Myers Squibb |
Status |
Discovery |
Programme |
Various |
Therapeutic area/Indication |
Oncology - solid tumours |
Partner |
Bristol Myers Squibb |
Status |
Discovery |
Programme |
Various |
Therapeutic area/Indication |
Immunology & Inflammation - Tissue Fibrosis |
Partner |
Pfizer |
Status |
Discovery |
Programme |
TargetPicV |
Therapeutic area/Indication |
Antiviral |
Partner |
Bayer/Haplogen |
Status |
Discovery |
Programme |
Various |
Therapeutic area/Indication |
Polycystic Ovary Syndrome |
Partner |
Bayer/Celmatix |
Status |
Discovery |
Programme |
Various |
Therapeutic area/Indication |
Nephrology |
Partner |
Novo Nordisk |
Status |
Discovery |
Programme |
ND |
Therapeutic area/Indication |
Oncology |
Partner |
Breakpoint Therapeutics |
Status |
Discovery |
Programme |
ND |
Therapeutic area/Indication |
Anti-infectives |
Partner |
Forge Therapeutics |
Status |
Discovery |
Programme |
ND |
Therapeutic area/Indication |
FSHD |
Partner |
Facio Therapies |
Status |
Discovery |
Programme |
INDY inhibitor |
Therapeutic area/Indication |
Metabolic |
Partner |
Eternygen |
Status |
Discovery |
Programme |
ND |
Therapeutic area/Indication |
Fibrotic disease |
Partner |
Fibrocor/Galapagos |
Status |
Discovery |
Programme |
ND |
Therapeutic area/Indication |
Gaucher |
Partner |
Centogene |
Status |
Discovery |
Programme |
Various |
Therapeutic area/Indication |
Various |
Partner |
Topas Therapeutics |
Status |
Discovery |
Programme |
ND |
Therapeutic area/Indication |
Heart failure |
Partner |
UKE |
Status |
Discovery |
Programme |
Various |
Therapeutic area/Indication |
Various |
Partner |
LAB282 / LAB150 / LAB591 / LAB031 / LAB10x / Autobahn Labs |
Status |
Discovery |
Programme |
Various |
Therapeutic area/Indication |
Anti-infectives |
Partner |
>5 programmes |
Status |
Discovery |
Programme |
Various |
Therapeutic area/Indication |
Internal: Oncology, CNS, Metabolic, Pain & Inflammtion, Immunology and Anti-invectives |
Partner |
>40 further programmes |
Status |
Discovery |